FDA Places Clinical Hold on Biohaven Epilepsy Drug After Rodent Study Findings

By Dr. Zubair Khalid, DVM, MS, PhD ·

FDA Places Clinical Hold on Biohaven Epilepsy Drug After Rodent Study Findings

The U.S. Food and Drug Administration has placed a hold on enrollment in clinical trials of Biohaven’s epilepsy drug candidate BHV-7000. The hold comes in response to findings from rodent tests.

Biohaven announced the regulatory action days after the drug had attracted a pending $350 million deal. The financial agreement covers the development of BHV-7000, but the FDA hold now places the program in an uncertain position.

The FDA has not authorized new patient enrollment while Biohaven addresses the findings from the animal studies. The company will need to work with regulators to resolve the issues before trials can continue.

Preclinical rodent studies are a standard part of drug safety testing. Findings in animal models can signal potential toxic effects that require further evaluation before a drug can be tested in humans. The FDA’s decision highlights how animal data can directly affect the timeline and commercial value of a drug candidate.

For biotech companies, a clinical hold is a significant setback, especially when a deal has been structured around the asset’s progress. The outcome for BHV-7000 will depend on Biohaven’s response to the agency and the nature of the rodent findings.

Source: original report

Key Takeaways

  • The FDA placed a clinical hold on enrollment in Biohaven's epilepsy drug candidate BHV-7000 trials after findings from rodent studies raised safety concerns.
  • Rodent studies are standard preclinical safety tests, and abnormal findings can signal potential toxic effects that require further evaluation before human testing proceeds.
  • The FDA has not authorized new patient enrollment for BHV-7000 until Biohaven addresses the animal study findings and works with regulators to resolve the issues.
  • The clinical hold occurred days after BHV-7000 attracted a pending $350 million development deal, placing the program's timeline and commercial value in an uncertain position.
  • Biohaven must respond to the FDA and clarify the nature of the rodent findings to lift the hold and continue clinical trials for BHV-7000.